US2003114397A1PendingUtilityA1

Water soluble paclitaxel derivatives

62
Assignee: PG TXL CO LPPriority: Mar 12, 1996Filed: Sep 12, 2002Published: Jun 19, 2003
Est. expiryMar 12, 2016(expired)· nominal 20-yr term from priority
Inventors:Chun LiSidney WallaceDong-Fang YuDavid J. Yang
A61K 47/645A61L 2300/416A61L 31/16A61K 38/13A61K 51/0497A61K 2123/00A61K 51/065A61L 2300/606A61K 41/0038A61P 35/02A61L 31/10A61K 47/60A61K 31/4375A61P 35/00A61K 47/547A61K 31/337C08G 73/1092A61K 47/59A61P 35/04A61K 2121/00
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for treating cancer in a subject, comprising administering to a subject having cancer a water soluble conjugate comprising a taxoid in combination with an antibiotic.  
     
     
         2 . The method of  claim 1 , wherein said water soluble conjugate comprises paclitaxel.  
     
     
         3 . The method of  claim 1 , wherein said water soluble conjugate comprises docetaxel.  
     
     
         4 . The method of  claim 2 , wherein said water soluble conjugate comprises a water soluble polymer conjugated to said paclitaxel.  
     
     
         5 . The method of  claim 4 , wherein said water soluble polymer is polyglutamate.  
     
     
         6 . The method of  claim 5 , wherein said polyglutamate is poly(l-glutamic acid).  
     
     
         7 . The method of  claim 6 , wherein said polyglutamic acid has a molecular weight of about 5000 to about 100,000 daltons.  
     
     
         8 . The method of  claim 7 , wherein said polyglutamic acid has a molecular weight of about 20,000 to about 80,000 daltons.  
     
     
         9 . The method of  claim 8 , wherein said polyglutamic acid has a molecular weight of about 25,000 to about 50,000 daltons.  
     
     
         10 . The method of  claim 9 , wherein said polyglutamic acid has a molecular weight of about 35,000 daltons.  
     
     
         11 . The method of  claim 6 , wherein said composition comprises from about 2% to about 35% by weight of paclitaxel.  
     
     
         12 . The method of  claim 6 , wherein said composition comprises from about 37% by weight of paclitaxel.  
     
     
         13 . The method of  claim 6 , wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.  
     
     
         14 . The method of  claim 12 , wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.  
     
     
         15 . The method of  claim 3 , wherein said water soluble conjugate comprises a water soluble polymer conjugated to said docetaxel.  
     
     
         16 . The method of  claim 15 , wherein said water soluble polymer is polyglutamate.  
     
     
         17 . The method of  claim 16 , wherein said polyglutamate is poly(l-glutamic acid).  
     
     
         18 . The method of  claim 17 , wherein said polyglutamic acid has a molecular weight of about 5000 to about 100,000 daltons.  
     
     
         19 . The method of  claim 18 , wherein polyglutamic acid has a molecular weight of about 20,000 to about 80,000 daltons.  
     
     
         20 . The method of  claim 19 , wherein polyglutamic acid has a molecular weight of about 25,000 to about 50,000 daltons.  
     
     
         21 . The method of  claim 20 , wherein said polyglutamic acid has a molecular weight of about 35,000 daltons.  
     
     
         22 . The method of  claim 17 , wherein said composition comprises from about 2% to about 35% by weight of said docetaxel.  
     
     
         23 . The method of  claim 17 , wherein said composition comprises from about 37% by weight of said docetaxel.  
     
     
         24 . The method of  claim 22 , wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.  
     
     
         25 . The method of  claim 23 , wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.  
     
     
         26 . A method for treating cancer in a subject, comprising administering to a subject having cancer a water soluble conjugate comprising a taxoid in combination with doxorubicin.  
     
     
         27 . The method of  claim 26 , wherein said water soluble conjugate comprises paclitaxel.  
     
     
         28 . The method of  claim 26 , wherein said water soluble conjugate comprises docetaxel.  
     
     
         29 . The method of  claim 27 , wherein said water soluble conjugate comprises a water soluble polymer conjugated to said paclitaxel.  
     
     
         30 . The method of  claim 29 , wherein said water soluble polymer is polyglutamate.  
     
     
         31 . The method of  claim 30 , wherein said polyglutamate is poly(l-glutamic acid).  
     
     
         32 . The method of  claim 31 , wherein said polyglutamic acid has a molecular weight of about 5000 to about 100,000 daltons.  
     
     
         33 . The method of  claim 32 , wherein said polyglutamic acid has a molecular weight of about 20,000 to about 80,000 daltons.  
     
     
         34 . The method of  claim 33 , wherein said polyglutamic acid has a molecular weight of about 25,000 to about 50,000 daltons.  
     
     
         35 . The method of  claim 34 , wherein said polyglutamic acid has a molecular weight of about 35,000 daltons.  
     
     
         36 . The method of  claim 31 , wherein said composition comprises from about 2% to about 35% by weight of paclitaxel.  
     
     
         37 . The method of  claim 31 , wherein said composition comprises from about 37% by weight of paclitaxel.  
     
     
         38 . The method of  claim 31 , wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.  
     
     
         39 . The method of  claim 37 , wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.  
     
     
         40 . The method of  claim 28 , wherein said water soluble conjugate comprises a water soluble polymer conjugated to said docetaxel.  
     
     
         41 . The method of  claim 40 , wherein said water soluble polymer is polyglutamate.  
     
     
         42 . The method of  claim 41 , wherein said polyglutamate is poly(l-glutamic acid).  
     
     
         43 . The method of  claim 42 , wherein said polyglutamic acid has a molecular weight of about 5000 to about 100,000 daltons.  
     
     
         44 . The method of  claim 43 , wherein polyglutamic acid has a molecular weight of about 20,000 to about 80,000 daltons.  
     
     
         45 . The method of  claim 44 , wherein polyglutamic acid has a molecular weight of about 25,000 to about 50,000 daltons.  
     
     
         46 . The method of  claim 45 , wherein said polyglutamic acid has a molecular weight of about 35,000 daltons.  
     
     
         47 . The method of  claim 42 , wherein said composition comprises from about 2% to about 35% by weight of said docetaxel.  
     
     
         48 . The method of  claim 42 , wherein said composition comprises from about 37% by weight of said docetaxel.  
     
     
         49 . The method of  claim 47 , wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.  
     
     
         50 . The method of  claim 48 , wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.  
     
     
         51 . A method for treating cancer in a subject, comprising administering to a subject having cancer a water soluble conjugate comprising a taxoid in combination with daunorubicin.  
     
     
         52 . The method of  claim 51 , wherein said water soluble conjugate comprises paclitaxel.  
     
     
         53 . The method of  claim 51 , wherein said water soluble conjugate comprises docetaxel.  
     
     
         54 . The method of  claim 52 , wherein said water soluble conjugate comprises a water soluble polymer conjugated to said paclitaxel.  
     
     
         55 . The method of  claim 54 , wherein said water soluble polymer is polyglutamate.  
     
     
         56 . The method of  claim 55 , wherein said polyglutamate is poly(l-glutamic acid).  
     
     
         57 . The method of  claim 56 , wherein said polyglutamic acid has a molecular weight of about 5000 to about 100,000 daltons.  
     
     
         58 . The method of  claim 57 , wherein said polyglutamic acid has a molecular weight of about 20,000 to about 80,000 daltons.  
     
     
         59 . The method of  claim 58 , wherein said polyglutamic acid has a molecular weight of about 25,000 to about 50,000 daltons.  
     
     
         60 . The method of  claim 59 , wherein said polyglutamic acid has a molecular weight of about 35,000 daltons.  
     
     
         61 . The method of  claim 56 , wherein said composition comprises from about 2% to about 35% by weight of paclitaxel.  
     
     
         62 . The method of  claim 56 , wherein said composition comprises from about 37% by weight of paclitaxel.  
     
     
         63 . The method of  claim 56 , wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.  
     
     
         64 . The method of  claim 62 , wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.  
     
     
         65 . The method of  claim 53 , wherein said water soluble conjugate comprises a water soluble polymer conjugated to said docetaxel.  
     
     
         66 . The method of  claim 65 , wherein said water soluble polymer is polyglutamate.  
     
     
         67 . The method of  claim 66 , wherein said polyglutamate is poly(l-glutamic acid).  
     
     
         68 . The method of  claim 67 , wherein said polyglutamic acid has a molecular weight of about 5000 to about 100,000 daltons.  
     
     
         69 . The method of  claim 68 , wherein polyglutamic acid has a molecular weight of about 20,000 to about 80,000 daltons.  
     
     
         70 . The method of  claim 69 , wherein polyglutamic acid has a molecular weight of about 25,000 to about 50,000 daltons.  
     
     
         71 . The method of  claim 70 , wherein said polyglutamic acid has a molecular weight of about 35,000 daltons.  
     
     
         72 . The method of  claim 67 , wherein said composition comprises from about 2% to about 35% by weight of said docetaxel.  
     
     
         73 . The method of  claim 67 , wherein said composition comprises from about 37% by weight of said docetaxel.  
     
     
         74 . The method of  claim 72 , wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.  
     
     
         75 . The method of  claim 73 , wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.